292 related articles for article (PubMed ID: 22289989)
1. Integrated genomic analyses identify WEE1 as a critical mediator of cell fate and a novel therapeutic target in acute myeloid leukemia.
Porter CC; Kim J; Fosmire S; Gearheart CM; van Linden A; Baturin D; Zaberezhnyy V; Patel PR; Gao D; Tan AC; DeGregori J
Leukemia; 2012 Jun; 26(6):1266-76. PubMed ID: 22289989
[TBL] [Abstract][Full Text] [Related]
2. RNAi screening of the kinome with cytarabine in leukemias.
Tibes R; Bogenberger JM; Chaudhuri L; Hagelstrom RT; Chow D; Buechel ME; Gonzales IM; Demuth T; Slack J; Mesa RA; Braggio E; Yin HH; Arora S; Azorsa DO
Blood; 2012 Mar; 119(12):2863-72. PubMed ID: 22267604
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Wee1 sensitizes cancer cells to antimetabolite chemotherapeutics in vitro and in vivo, independent of p53 functionality.
Van Linden AA; Baturin D; Ford JB; Fosmire SP; Gardner L; Korch C; Reigan P; Porter CC
Mol Cancer Ther; 2013 Dec; 12(12):2675-84. PubMed ID: 24121103
[TBL] [Abstract][Full Text] [Related]
4. CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo.
Chaudhuri L; Vincelette ND; Koh BD; Naylor RM; Flatten KS; Peterson KL; McNally A; Gojo I; Karp JE; Mesa RA; Sproat LO; Bogenberger JM; Kaufmann SH; Tibes R
Haematologica; 2014 Apr; 99(4):688-96. PubMed ID: 24179152
[TBL] [Abstract][Full Text] [Related]
5. Tumour suppressive effects of WEE1 gene silencing in breast cancer cells.
Ghiasi N; Habibagahi M; Rosli R; Ghaderi A; Yusoff K; Hosseini A; Abdullah S; Jaberipour M
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6605-11. PubMed ID: 24377575
[TBL] [Abstract][Full Text] [Related]
6. A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations.
Zhou L; Zhang Y; Chen S; Kmieciak M; Leng Y; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Dai Y; Grant S
Leukemia; 2015 Apr; 29(4):807-18. PubMed ID: 25283841
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of ubiquitin-specific protease 7 sensitizes acute myeloid leukemia to chemotherapy.
Cartel M; Mouchel PL; Gotanègre M; David L; Bertoli S; Mansat-De Mas V; Besson A; Sarry JE; Manenti S; Didier C
Leukemia; 2021 Feb; 35(2):417-432. PubMed ID: 32447346
[TBL] [Abstract][Full Text] [Related]
8. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
[TBL] [Abstract][Full Text] [Related]
9. The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.
Zhou L; Chen S; Zhang Y; Kmieciak M; Leng Y; Li L; Lin H; Rizzo KA; Dumur CI; Ferreira-Gonzalez A; Rahmani M; Povirk L; Chalasani S; Berger AJ; Dai Y; Grant S
Blood; 2016 May; 127(18):2219-30. PubMed ID: 26851293
[TBL] [Abstract][Full Text] [Related]
10. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
Mizuarai S; Yamanaka K; Itadani H; Arai T; Nishibata T; Hirai H; Kotani H
Mol Cancer; 2009 Jun; 8():34. PubMed ID: 19500427
[TBL] [Abstract][Full Text] [Related]
11. NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Metzelder SK; Michel C; von Bonin M; Rehberger M; Hessmann E; Inselmann S; Solovey M; Wang Y; Sohlbach K; Brendel C; Stiewe T; Charles J; Ten Haaf A; Ellenrieder V; Neubauer A; Gattenlöhner S; Bornhäuser M; Burchert A
Leukemia; 2015 Jul; 29(7):1470-7. PubMed ID: 25976987
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of MTSS1 in acute myeloid leukemia is associated with a poor prognosis, chemotherapy resistance, and disease aggressiveness.
Grandits AM; Nguyen CH; Schlerka A; Hackl H; Sill H; Etzler J; Heyes E; Stoiber D; Grebien F; Heller G; Wieser R
Leukemia; 2021 Oct; 35(10):2827-2839. PubMed ID: 33782537
[TBL] [Abstract][Full Text] [Related]
13. Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies.
Weisberg E; Nonami A; Chen Z; Liu F; Zhang J; Sattler M; Nelson E; Cowens K; Christie AL; Mitsiades C; Wong KK; Liu Q; Gray N; Griffin JD
Leukemia; 2015 Jan; 29(1):27-37. PubMed ID: 24791855
[TBL] [Abstract][Full Text] [Related]
14. CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells.
Qi W; Xie C; Li C; Caldwell JT; Edwards H; Taub JW; Wang Y; Lin H; Ge Y
J Hematol Oncol; 2014 Aug; 7():53. PubMed ID: 25084614
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation.
Tao YF; Li ZH; Du WW; Xu LX; Ren JL; Li XL; Fang F; Xie Y; Li M; Qian GH; Li YH; Li YP; Li G; Wu Y; Feng X; Wang J; He WQ; Hu SY; Lu J; Pan J
Oncol Rep; 2017 Mar; 37(3):1419-1429. PubMed ID: 28184925
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastoma.
Harris PS; Venkataraman S; Alimova I; Birks DK; Balakrishnan I; Cristiano B; Donson AM; Dubuc AM; Taylor MD; Foreman NK; Reigan P; Vibhakar R
Mol Cancer; 2014 Mar; 13():72. PubMed ID: 24661910
[TBL] [Abstract][Full Text] [Related]
19. Increased activity of both CDK1 and CDK2 is necessary for the combinatorial activity of WEE1 inhibition and cytarabine.
Garcia TB; Fosmire SP; Porter CC
Leuk Res; 2018 Jan; 64():30-33. PubMed ID: 29175378
[TBL] [Abstract][Full Text] [Related]
20. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.
Murrow LM; Garimella SV; Jones TL; Caplen NJ; Lipkowitz S
Breast Cancer Res Treat; 2010 Jul; 122(2):347-57. PubMed ID: 19821025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]